A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Carboplatin (Primary) ; Oregovomab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms FLORA-6
- Sponsors CanariaBio
- 23 Aug 2024 Status changed from recruiting to active, no longer recruiting as per CanariaBio media release.
- 12 Oct 2023 Primary endpoint (Progression-free survival (PFS) Rate at 12 months) has been met according to a Specialised Therapeutics Asia media release.
- 12 Oct 2023 Results published in the Specialised Therapeutics Asia media release.